News | March 20, 2025
ZIM Laboratories receives marketing authorization for Dimethyl Fumarate in Portugal
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Standalone profit from operations for Q4-2024 were Rs. 108 crore
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Subscribe To Our Newsletter & Stay Updated
